Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction

Circulation

Volumn 107, Issue 22, 2003, Pages 2793-2798

  Kühl, Uwe ^a   Pauschinger, Matthias ^b   Schwimmbeck, Peter Lothar ^b   Seeberg, Bettina ^b   Lober, Conny ^b   Noutsias, Michel ^b   Poller, Wolfgang ^b   Schultheiss, Heinz Peter ^b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b NONE

Author keywords

Biopsy; Cardiomyopathy; Heart failure; Viruses

Indexed keywords

BENEFERON; BETA INTERFERON;

ADENOVIRUS; ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERSISTENT VIRUS INFECTION; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; VIRUS DETECTION; VIRUS EXCRETION; VIRUS GENOME; VIRUS LOAD;

ADENOVIRIDAE; ANTIVIRAL AGENTS; BIOPSY; CARDIAC VOLUME; CARDIOMYOPATHY, DILATED; CELL COUNT; DISEASE PROGRESSION; ELECTROCARDIOGRAPHY; ENTEROVIRUS; FEMALE; HEART; HEMODYNAMIC PROCESSES; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MYOCARDIUM; POLYMERASE CHAIN REACTION; STROKE VOLUME; T-LYMPHOCYTES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0038120010     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000072766.67150.51     Document Type: Article

References (43)

1. Elliot P. Diagnosis and management of dilated cardiomyopathy. Eur Heart J. 2000;84:106-112.
2. Feldmann AM, McNamara D. Myocarditis. N Engl J Med. 2000;343:1388-1398.
3. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996;93:841-842.
4. Bowles NE, Richardson PJ, Olsen EG, et al. Detection of Coxsackie-Bvirus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet. 1986;1:1120-1123.
5. Tracy S, Wiegand V, McManus B, et al. Molecular approaches to enteroviral diagnosis in idiopathic cardiomyopathy and myocarditis. J Am Coll Cardiol. 1990;15:1688-1694.
6. Jin O, Sole MJ, Butany JW, et al. Detection of enterovirus RNA in myocardial biopsies from patients with myocarditis and cardiomyopathy using gene amplification by polymerase chain reaction. Circulation. 1990;82:8-16.
7. Archard LC, Bowles NE, Cunningham L, et al. Molecular probes for detection of persisting enterovirus infection of human heart and their prognostic value. Eur Heart J. 1991;12:56-59.
8. Koide H, Kitaura Y, Deguchi H, et al. Genomic detection of enteroviruses in the myocardium: studies on animal hearts with coxsackievirus B3 myocarditis and endomyocardial biopsies from patients with myocarditis and dilated cardiomyopathy. Jpn Circ J. 1992;56:1081-1093.
9. Grasso M, Arbustini E, Silini E, et al. Search for Coxsackievirus B3 RNA in idiopathic dilated cardiomyopathy using gene amplification by polymerase chain reaction. Am J Cardiol. 1992;69:658-664.
10. Baboonian C, Treasure T. Meta-analysis of the association of enteroviruses with human heart disease. Heart. 1997;78:539-543.
11. Pauschinger M, Doerner A, Kuehl U, et al. Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation. 1999;99:889-895.
12. Why HJ, Meany BT, Richardson PJ, et al. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation. 1994;89:2582-2589.
13. Fujioka S, Kitaura Y, Ukimura A, et al. Evaluation of viral infection in the myocardium of patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2000;36:1920-1926.
14. Heim A, Canu A, Kirschner P, et al. Synergistic interaction of interferon-beta and interferon-gamma in coxsackievirus B3-infected carrier cultures of human myocardial fibroblasts. J Infect Dis. 1992;166:958-965.
15. Matsumori A, Tomioka N, Kawai C. Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice. Am Heart J. 1988;115:1229-1232.
16. Pauschinger M, Bowles NE, Fuentes-Garcia FJ, et al. Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation. 1999;99:1348-1354.
17. Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol. 1987;18:619-624.
18. Kuhl U, Noutsias M, Seeberg B, et al. Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy. Heart. 1996;75:295-300.
19. Echocardiography CoM-mSotASo. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
20. Woodruff JF. Viral myocarditis: a review. Am J Pathol. 1980;101:425-484.
21. Feldman AM, McNamara D. Medical progress: myocarditis. N Engl J Med. 2000;343:1388-1398.
22. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death. Learning from the past for the future. Circulation. 1999;99:1091-1100.
23. Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation. 2001;104:1076-1082.
24. Archard LC, Khan MA, Soteriou BA, et al. Characterization of Coxsackie B virus RNA in myocardium from patients with dilated cardiomyopathy by nucleotide sequencing of reverse transcription-nested polymerase chain reaction products. Hum Pathol. 1998;29:578-584.
25. Frustaci A, Chimenti C, Calabrese F, et al. Immunosuppressive therapy for active lymphocytic myocarditis: virologic and immunologic profile of responders versus nonresponders. Circulation. 2003;107:857-863.
26. Wessely R, Henke A, Zell R, et al. Low-level expression of a mutant coxsackieviral cDNA induces a myocytopathic effect in culture: an approach to the study of enteroviral persistence in cardiac myocytes. Circulation. 1998;98:450-457.
27. Liu P, Aitken K, Kong Y, et al. The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease. Nature Med. 2000;6:429-434.
28. Klingel K, Rieger P, Mall G, et al. Visualization of enteroviral replication in myocardial tissue by ultrastructural in situ hybridization: identification of target cells and cytopathic effects. Lab Invest. 1998;78:1227-1237.
29. Badorff C, Lee GH, Lamphear BJ, et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med. 1999;5:320-326.
30. Doerner A, Pauschinger M, Schwimmbeck PL, et al. The shift in the myocardial adenine nucleotide translocator isoform expression pattern is associated with an enteroviral infection in the absence of an active T-cell dependent immune response in human inflammatory heart disease. J Am Coll Cardiol. 2000;35:1778-1784.
31. Badorff C, Fichtlscherer B, Rhoads RE, et al. Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation: a protective mechanism against enteroviral cardiomyopathy. Circulation. 2000;102:2276-2281.
32. Yamamoto N, Shibamori M, Ogura M, et al. Effects of intranasal administration of recombinant murine interferon-gamma on murine acute myocarditis caused by encephalomyocarditis virus. Circulation. 1998;97:1017-1023.
33. Wessely R, Klingel K, Knowlton KU, et al. Cardioselective infection with coxsackievirus B3 requires intact type I interferon signaling: implications for mortality and early viral replication. Circulation. 2001;103:756-761.
34. Horwitz MS, La Cava A, Fine C, et al. Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis. Nature Med. 2000;6:693-697.
35. Ramshaw IA, Ramsay A, Karupiah G, et al. Cytokines and immunity to viral infection. Immunol Rev. 1997;159:119-135.
36. Seko Y, Shinkai Y, Kawasaki A, et al. Evidence of perforin-mediated cardiac myocyte injury in acute murine myocarditis caused by Coxsackie virus B3. J Pathol. 1993;170:53-58.
37. Huang S, Hendrix W, Althage A, et al. Immune response in mice that lack the interferon-gamma receptor. Science. 1993;259:1742-1745.
38. Liu P, Aitken K, Kong YY, et al. The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease. Nat Med. 2000;6:429-434.
39. McCarthy RE, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (non-fulminant) myocarditis. N Engl J Med. 2000;342:734-735.
40. Figulla HR, Stille-Siegener M, Mall G, et al. Myocardial enterovirus infection with left ventricular dysfunction: a benign disease compared with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1995;25:1170-1175.
41. Miric M, Vasiljevic J, Bojic M, et al. Long-term follow up of patients with dilated heart muscle disease treated with human leucocytic interferon alpha or thymic hormones initial results. Heart. 1996;75:596-601.
42. Baykurt C, Caglar K, Ceviz N, et al. Successful treatment of Epstein-Barr virus infection associated with myocarditis. Pediatr Int. 1999;41:389-391.
43. Bozkurt B, Kribbs SB, Clubb FJ Jr, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97:1382-1391.